Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Clinical trial NCT04362137 · COMPLETED
Trial details
- NCT number
- NCT04362137
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-02
- Primary completion
- 2020-10-17
- Enrollment
- 432
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.